MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 131 filers reported holding MIRATI THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,613,600 | -63.8% | 60,000 | -70.0% | 0.86% | -63.9% |
| Q2 2023 | $7,226,000 | +38.8% | 200,000 | +42.9% | 2.38% | +55.1% |
| Q1 2023 | $5,205,000 | -42.6% | 140,000 | -30.0% | 1.54% | -60.2% |
| Q4 2022 | $9,062,000 | -25.9% | 200,000 | +14.3% | 3.87% | +12.8% |
| Q3 2022 | $12,222,000 | +65.5% | 175,000 | +59.1% | 3.43% | -10.8% |
| Q2 2022 | $7,384,000 | +349.1% | 110,000 | +450.0% | 3.85% | +977.3% |
| Q1 2022 | $1,644,000 | -62.6% | 20,000 | -33.3% | 0.36% | -77.4% |
| Q4 2021 | $4,401,000 | -58.5% | 30,000 | -50.0% | 1.58% | -49.2% |
| Q3 2021 | $10,615,000 | +31.4% | 60,000 | +20.0% | 3.10% | +39.8% |
| Q2 2021 | $8,077,000 | -5.7% | 50,000 | 0.0% | 2.22% | +10.3% |
| Q1 2021 | $8,565,000 | -61.0% | 50,000 | -50.0% | 2.01% | -58.9% |
| Q4 2020 | $21,964,000 | +120.5% | 100,000 | +66.7% | 4.89% | +69.9% |
| Q3 2020 | $9,963,000 | -43.7% | 60,000 | -61.3% | 2.88% | -38.3% |
| Q2 2020 | $17,696,000 | +100.2% | 155,000 | +34.8% | 4.67% | +99.1% |
| Q1 2020 | $8,840,000 | -54.3% | 115,000 | -23.3% | 2.34% | -36.3% |
| Q4 2019 | $19,329,000 | -9.8% | 150,000 | -45.5% | 3.68% | -32.6% |
| Q3 2019 | $21,425,000 | -37.9% | 275,000 | -17.9% | 5.46% | -23.7% |
| Q2 2019 | $34,505,000 | +213.8% | 335,000 | +123.3% | 7.16% | +149.1% |
| Q1 2019 | $10,995,000 | -35.2% | 150,000 | -62.5% | 2.87% | -53.3% |
| Q4 2018 | $16,968,000 | -51.0% | 400,000 | -45.6% | 6.16% | -16.3% |
| Q3 2018 | $34,633,000 | +40.5% | 735,300 | +47.1% | 7.36% | +1.5% |
| Q2 2018 | $24,650,000 | +205.9% | 500,000 | +90.5% | 7.25% | +345.0% |
| Q1 2018 | $8,059,000 | -26.4% | 262,500 | -56.2% | 1.63% | -36.5% |
| Q4 2017 | $10,950,000 | +1123.5% | 600,000 | +248.5% | 2.57% | +1437.7% |
| Q1 2017 | $895,000 | +9.4% | 172,184 | 0.0% | 0.17% | -15.2% |
| Q4 2016 | $818,000 | -55.0% | 172,184 | -37.4% | 0.20% | -33.2% |
| Q3 2016 | $1,818,000 | +343.4% | 275,000 | +266.7% | 0.30% | +150.0% |
| Q2 2016 | $410,000 | -92.3% | 75,000 | -70.0% | 0.12% | -96.1% |
| Q1 2016 | $5,350,000 | -32.3% | 250,000 | 0.0% | 3.03% | -6.4% |
| Q4 2015 | $7,900,000 | – | 250,000 | – | 3.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $688,784,000 | 67.42% |
| Avoro Capital Advisors LLC | 4,535,000 | $996,067,000 | 17.15% |
| Darwin Global Management, Ltd. | 260,876 | $57,299,000 | 15.99% |
| Boxer Capital, LLC | 1,765,560 | $387,788,000 | 12.46% |
| Perceptive Advisors | 3,693,516 | $811,244,000 | 8.71% |
| Consonance Capital Management LP | 330,000 | $72,481,000 | 6.77% |
| EcoR1 Capital, LLC | 464,298 | $101,978,000 | 5.48% |
| Fairmount Funds Management LLC | 60,500 | $13,288,000 | 4.75% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,400 | $14,804,000 | 4.04% |
| RTW INVESTMENTS, LP | 1,054,364 | $231,581,000 | 3.88% |